Table 2.

Relative mRNA levels of DNA repair and Fanconi anemia genes

Gene symbolGene nameOV-HR2OV-CA4
Fold change, n (range)CallFold change, n (range)Call
ATRAtaxia telangiectasia, Rad3-related1.9 (1.7-2.1)UP *2.1 (1.7-2.5)DN
BIDBH3 interacting domain death agonist1.5 (1.3-1.8)UP2.7 (2.2-3.3)DN
BLMBloom syndrome1.3 (1.1-1.5)DN4.0 (3.6-4.5)DN
DCLRE1CDNA cross-link repair 1C (PSO2 homologue, Saccharomyces cerevisiae)1.3 (1.3-1.4)DN1.6 (1.4-1.8)DN
ERCC1Excision repair cross-complementing rodent repair deficiency 11.2 (1.1-1.3)DN1.3 (0.9-1.9)DN
ERCC4Excision repair cross-complementing rodent repair deficiency 22.0 (1.3-2.8)UP1.3 (1.1-1.5)DN
H2AFXH2A histone family, member X2.5 (2.0-3.2)UP1.2 (1.0-1.5)UP
HTATIPHIV-1 Tat interactive protein, 60 kDa1.0 (0.9-1.1)1.1 (0.8-1.5)
MRE11AMitotic recombination 111.0 (0.7-1.5)1.1 (0.9-1.3)
NBNNibrin, p95 protein of MRE11/RAD50 complex1.1 (1.0-1.2)1.0 (0.8-1.3)
RAD51RAD51 homologue1.4 (1.0-1.8)DN2.3 (1.8-3.0)DN
RAD54LRAD54-like (S. cerevisiae)1.8 (1.5-2.1)DN1.6 (1.3-1.9)DN
REV3LREV3-like, catalytic subunit of DNA polymerase ζ (yeast)1.9 (1.5-2.3)UP2.2 (1.5-3.1)DN
TP53Tumor protein p531.15 down (1.10-1.20)1.16 up (1.13-1.20)
XRCC2X-ray repair complementing defective repair in CHO cells 21.1 (0.9-1.3)1.0 (0.6-1.8)
XRCC3X-ray repair complementing defective repair in CHO cells 31.5 (1.3-1.9)DN1.1 (0.8-1.4)
FANCAFanconi anemia complementation group A1.4 (1.1-1.9)DN1.1 (0.9-1.3)
FANCCFanconi anemia complementation group C1.0 (0.6-1.6)1.2 (0.7-2.3)DN
FANCD2Fanconi anemia complementation group D26.4 (4.6-6.9)DN5.0 (4.1-6.6)DN
FANCEFanconi anemia complementation group E1.6 (1.1-1.8)DN1.1 (1.0-1.2)
FANCFFanconi anemia complementation group F1.9 (1.1-3.2)UP1.2 (0.7-2.2)UP
FANCGFanconi anemia complementation group G1.4 (1.1-1.8)DN3.1 (2.5-3.7)DN
FANCLFanconi anemia complementation group L1.9 (1.8-2.1)DN1.8 (1.1-3.0)DN
FANCMFanconi anemia complementation group M2.3 (2.2-2.3)DN1.9 (1.5-2.4)DN
  • * An increase of 1.2-fold or more of the indicated mRNA in patient sample compared with normal control.

  • A decrease of 1.2-fold or more in patient sample compared with normal control.

  • No difference in mRNA level between patient and normal control.